Back to Agenda
[V6-S2] Think about the Exit Strategy in Drug Discovery Processes of Academia
Session Chair(s)
Kotone Matsuyama, RPh
Professor, Department of Health Policy and Management
Nippon Medical School, Japan
In recent years, industry-academia collaboration has progressed in the field of drug / medical device development, and worldwide innovative new drug / treatment method from domestic academia has become a reality. When Academia conducts drug discovery research, it is important that both company and academia collaborate with early stages of development, because it will be manufactured and sold by a company, finally. However, academia researchers are not professionals of development, and there are cases where it is difficult to negotiate before cooperation. In this session, we will clarify the “gap between what each other wishes and what is required”, and also based on actual examples overcoming this, we will discuss the ideal way of cooperation approaches of industry, government, academia from their respective perspectives.
Speaker(s)
Role of PMDA for Drug Development
Hisashi Koike, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Review Director, Office of New Drug IV
Actual Developmental Strategy for Regenerative Medicine Products
Hiroshi Hayashi, MS
Hokkaido University Hospital, Japan
Clinical Research and Medical Innovation Center
First SAKIGAKE Designated Medical Device to Treat Adductor Spasmodic Dysphonia
Tetsuji Sanuki, MD, PhD
Nagoya City University, Japan
Associate Professor, Graduate School of Medical Sciences
Yuki Otsuka
Tohoku University Hospital, Japan
Clinical Research Innovation and Education Center Tohoku University Hospital
Shinichi Torii
Biogen Japan Ltd., Japan
Have an account?